Source comparison
TB-500 Research Geriatric Considerations: Protocol Comparison
Dose Titration Period 2–3 weeks 4–6 weeks Reduced renal clearance and hepatic enzyme activity require gradual dose escalation to avoid acute toxicity in aging models Extend titration by 100% in subjects over 65 to allow clearance pathway adaptation Per-Dose Co
This comparison does not assign a generated winner or score.
- Dose Titration Period
- 2–3 weeks
- 4–6 weeks
- Reduced renal clearance and hepatic enzyme activity require gradual dose escalation to avoid acute toxicity in aging models
- Extend titration by 100% in subjects over 65 to allow clearance pathway adaptation
- Per-Dose Concentration
- 5 mg/kg twice weekly
- 3.5 mg/kg twice weekly OR 5 mg/kg once weekly
- Prolonged peptide half-life due to decreased GFR means lower per-dose amounts achieve equivalent AUC exposure
- Reduce dose by 20–30% or frequency by 50%. Not both. To maintain therapeutic window
- Treatment Duration
- 4–6 weeks post-intervention
- 6–10 weeks post-intervention
- Aging tissue shows 40–60% slower collagen turnover and cellular proliferation, delaying endpoint achievement
- Plan for 150% longer observation periods; interim measurements at weeks 3, 6, and 9 distinguish delayed response from non-response
- Baseline Senescent Cell Measurement
- Not required
- Mandatory (p16INK4a or SA-beta-gal assay)
- High senescent cell burden (>15% p16+ cells) predicts poor TB-500 response due to SASP interference with regenerative signalling
- Subjects with >20% senescent cell load should be excluded or pre-treated with senolytics before TB-500 administration
- Renal Function Monitoring
- Optional
- Required (creatinine, cystatin C every 2 weeks)
- TB-500 clearance depends heavily on GFR; undetected renal insufficiency causes dose accumulation and off-target effects
- Adjust dose downward by 25% for every 10 mL/min drop in estimated GFR below baseline
- This table reflects the core protocol adjustments that distinguish geriatric TB-500 research from standard young-adult models. The 'Bottom Line' column provides actionable thresholds researchers can apply directly to study design.